Investors

CPP aims to be a global leader in the development of pharmaceutical agents, acting alone or in combinations, that will effectively and safely reduce the risk of cancers in patients with genetic risk factors, such as familial adenomatous polyposis (FAP) or prior conditions that increase risk of cancer, such as colon polyps, Barrett's esophagus, prostatic intraepithelial neoplasia and dysplastic nevi of the skin.

CPP is seeking $20 million in equity financing to support its efforts over the next three years. This will allow the Company to complete a pivotal trial in Familial Adenomatous Polyposis (FAP) and file a New Drug Application (NDA) with the FDA. The financing effort will also support another NDA/registration-trial in Colon Adenoma Therapy (CAT) that will be co-sponsored with the National Cancer Institute (NCI) and conducted by the Southwest Oncology Group (SWOG). CPP will also support a PI/II Neuroblastoma (NB) trial and a clinical urinary biomarker trial, and will contribute to additional NCI-funded trials.

We believe the time is right to apply "Risk Reduction" paradigms to cancer because of the ...

Potential to Impact Cancer Death Rates in a Significant Way

  • Traditional chemotherapy and even newer "targeted therapy" appear to make only marginal improvements.
  • Lessons from cholesterol-lowering medicines, blood-pressure medicines, and vaccines.

    Biomarkers and Critical Path Initiative
  • The age of biomarkers and regulatory receptivity.
  • FDA has agreed to adenomas as a clinically relevant end point for colon cancer.
  • Others are on the way.

    Economics
  • Reimbursement rules are changing for expensive treatments with incremental improvements in survival.
  • "We can't afford not to prevent."

    CPP is uniquely positioned to make it happen.

    Please contact Jeffrey Jacob at jjacob@canprevent.com or
    (520) 908-7774 for more information.